MA27736A1 - Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose - Google Patents

Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose

Info

Publication number
MA27736A1
MA27736A1 MA28459A MA28459A MA27736A1 MA 27736 A1 MA27736 A1 MA 27736A1 MA 28459 A MA28459 A MA 28459A MA 28459 A MA28459 A MA 28459A MA 27736 A1 MA27736 A1 MA 27736A1
Authority
MA
Morocco
Prior art keywords
derivatives
cyclohexanecarbonylaminobutyric
phenyloxazol
ylmethoxy
arteriosclerosis
Prior art date
Application number
MA28459A
Other languages
English (en)
Inventor
Christian Stapper
Dirk Gretzke
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Heiner Glombik
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27736A1 publication Critical patent/MA27736A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne des dérivés d'acide aminé à substitution cycloalkyle, ainsi que des sels de ceux-ci, compatibles d'un point de vue physiologique, et des dérivés de ceux-ci, fonctionnels d'un point de vue physiologique. Elle concerne des composés de formule (I), dans laquelle les radicaux ont les significations données, ainsi que des sels de ceux-ci, acceptables d'un point de vue physiologique, et des procédés pour les produire. Ces composés permettent de traiter et/ou de prévenir des troubles du métabolisme des acides gras et des troubles d'utilisation du glucose, ainsi que des troubles avec lesquels une résistance à l'insuline joue un rôle.
MA28459A 2003-02-27 2005-08-26 Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose MA27736A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MA27736A1 true MA27736A1 (fr) 2006-02-01

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
MA28465A MA27742A1 (fr) 2003-02-27 2005-08-26 Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.
MA28459A MA27736A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
MA28460A MA27737A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA28465A MA27742A1 (fr) 2003-02-27 2005-08-26 Les dérivés et les composés correspondants à l'acide 4-(3-(2-phénelozol-4-ylméthoxy)cyclohexyloxy)butanoique comme modulateurs du PPAR dans le traitement du diabète de Type 2 et de l'athérosclérose.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA28460A MA27737A1 (fr) 2003-02-27 2005-08-26 Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose

Country Status (34)

Country Link
US (5) US7335671B2 (fr)
EP (3) EP1599452B1 (fr)
JP (3) JP2006519193A (fr)
KR (3) KR20050105492A (fr)
CN (3) CN100439345C (fr)
AR (3) AR043433A1 (fr)
AT (3) ATE430738T1 (fr)
AU (3) AU2004215673B2 (fr)
BR (3) BRPI0407758A (fr)
CA (3) CA2516620A1 (fr)
CL (2) CL2004000391A1 (fr)
CO (2) CO5690580A2 (fr)
DE (4) DE10308355A1 (fr)
DK (3) DK1599455T3 (fr)
EC (2) ECSP055985A (fr)
ES (3) ES2329366T3 (fr)
HR (3) HRP20050742A2 (fr)
IL (2) IL170316A (fr)
MA (3) MA27742A1 (fr)
MX (3) MXPA05008951A (fr)
NO (3) NO20054398L (fr)
OA (2) OA13034A (fr)
PA (1) PA8596801A1 (fr)
PE (3) PE20040959A1 (fr)
PL (3) PL378437A1 (fr)
PT (3) PT1599452E (fr)
RS (1) RS20050594A (fr)
RU (3) RU2005129992A (fr)
SA (1) SA04250153A (fr)
TN (2) TNSN05206A1 (fr)
TW (3) TW200500349A (fr)
UY (2) UY28209A1 (fr)
WO (3) WO2004076427A1 (fr)
ZA (2) ZA200505765B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP2052728B1 (fr) 2006-08-10 2018-06-13 mimozax Co., Ltd. Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
JP5340287B2 (ja) 2007-08-16 2013-11-13 ソルヴェイ(ソシエテ アノニム) 4−フルオロ置換3−オキソ−アルカン酸のエステル類の調製方法
NZ587261A (en) * 2008-02-29 2012-05-25 Nissan Chemical Ind Ltd Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
ES2932091T3 (es) 2017-12-13 2023-01-11 Canon Kk Cartucho y dispositivo de formación de imágenes
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
WO1997041097A2 (fr) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Nouveaux composes heterocycliques, leur procede de preparation, compositions pharmaceutiques les contenant et utilisation de ces composes dans le traitement du diabete et des maladies associees
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
AU757693B2 (en) 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
EP1108713A4 (fr) * 1998-08-27 2006-04-05 Ono Pharmaceutical Co Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (fr) 1999-04-16 2002-01-23 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
NZ515087A (en) * 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
JP2002543200A (ja) 1999-04-30 2002-12-17 ニューロゲン コーポレイション 9H−ピリミド[4、5−b]インドール誘導体:CRF1特異性リガンド
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
EP1194146B1 (fr) 1999-06-18 2006-07-19 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
WO2001004146A2 (fr) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Polypeptides d'ecarine, polynucleotides codant pour l'ecarine, et procedes d'utilisation associes
CA2378878A1 (fr) 1999-07-29 2001-02-08 Jeffrey Thomas Mullaney Benzofurylpiperazines et benzofurylhomopiperazines: antagonistes de la serotonine
CA2383781A1 (fr) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Derives de sulfonylcarboxamide, leur procede de production et leur utilisation comme medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
AU773777B2 (en) 1999-12-03 2004-06-03 Astrazeneca Ab Crystalline form of (S)-2 ethoxy-3-(4-(2-(4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
JP2003528135A (ja) 2000-03-31 2003-09-24 プロバイオドラッグ アーゲー 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
AU4882801A (en) 2000-04-25 2001-11-07 Kyorin Pharmaceutical Co. Ltd. Novel stable crystal of thiazolidinedione derivative and process for producing the same
WO2001083451A1 (fr) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Nouveaux composés bicycliques
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ スクイブ カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
EP1289526A4 (fr) 2000-05-30 2005-03-16 Merck & Co Inc Agonistes du recepteur de la melanocortine
AU6231801A (en) 2000-06-09 2001-12-17 Aventis Pharma Gmbh Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (fr) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Procédé pour l'identification de composés inhibant la protéolyse de IkB par l'ubiquitine
DK1313716T3 (da) * 2000-08-23 2007-08-27 Lilly Co Eli Oxazolyl-arylpropionsyrederivater og anvendelse deraf som PPAR-agonister
CA2420178A1 (fr) 2000-08-23 2002-03-07 Eli Lilly And Company Derives d'acide oxazolyl-aryloxyacetique et leur utilisation comme agonistes des ppar
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
IL156550A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
NZ526687A (en) * 2000-12-25 2004-08-27 Ono Pharmaceutical Co Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE60216094T2 (de) * 2001-06-07 2007-06-06 Eli Lilly And Co., Indianapolis Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (fr) 2001-07-03 2003-01-16 Biovitrum Ab Procedes d'identification de composes modulant l'activite du ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
BR0212158A (pt) 2001-08-31 2004-07-13 Aventis Pharma Gmbh Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Pparモジュレーターとして用いるためのウレアリンカー誘導体
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
US7872034B2 (en) 2011-01-18
JP2006519199A (ja) 2006-08-24
US20050101637A1 (en) 2005-05-12
TNSN05204A1 (en) 2007-06-11
MXPA05008995A (es) 2005-10-18
US7259177B2 (en) 2007-08-21
MXPA05008988A (es) 2005-10-18
AU2004215673B2 (en) 2009-10-01
ES2326418T3 (es) 2009-10-09
PL377735A1 (pl) 2006-02-20
WO2004076428A1 (fr) 2004-09-10
TW200510352A (en) 2005-03-16
MXPA05008951A (es) 2005-11-04
ATE430738T1 (de) 2009-05-15
CN100439347C (zh) 2008-12-03
AU2004215677A1 (en) 2004-09-10
ZA200505768B (en) 2005-11-23
MA27737A1 (fr) 2006-02-01
WO2004076427A1 (fr) 2004-09-10
US20040209920A1 (en) 2004-10-21
EP1599453B1 (fr) 2009-05-06
CL2004000391A1 (es) 2005-01-07
OA13035A (en) 2006-11-10
PE20050292A1 (es) 2005-05-24
NO20054396D0 (no) 2005-09-22
AR043427A1 (es) 2005-07-27
US7365084B2 (en) 2008-04-29
AU2004215672A1 (en) 2004-09-10
AU2004215673A1 (en) 2004-09-10
CN100439345C (zh) 2008-12-03
SA04250153A (ar) 2005-12-03
DE10308355A1 (de) 2004-12-23
WO2004076426A1 (fr) 2004-09-10
KR20050106462A (ko) 2005-11-09
DK1599455T3 (da) 2009-11-09
EP1599455B1 (fr) 2009-07-01
CA2517386A1 (fr) 2004-09-10
CL2004000392A1 (es) 2005-04-22
EP1599452B1 (fr) 2007-06-20
ATE365159T1 (de) 2007-07-15
KR20050106461A (ko) 2005-11-09
HRP20050742A2 (en) 2006-09-30
RU2005129995A (ru) 2006-01-27
PT1599452E (pt) 2007-09-12
JP2006519193A (ja) 2006-08-24
US7335671B2 (en) 2008-02-26
UY28210A1 (es) 2004-09-30
JP2006519194A (ja) 2006-08-24
PL378130A1 (pl) 2006-03-06
ES2329366T3 (es) 2009-11-25
ATE435217T1 (de) 2009-07-15
CO5690580A2 (es) 2006-10-31
OA13034A (en) 2006-11-10
EP1599453A1 (fr) 2005-11-30
CN1756748A (zh) 2006-04-05
PE20040959A1 (es) 2005-01-17
CN1753879A (zh) 2006-03-29
PT1599453E (pt) 2009-07-14
PL378437A1 (pl) 2006-04-03
BRPI0407907A (pt) 2006-02-14
CO5690578A2 (es) 2006-10-31
ECSP055986A (es) 2006-01-16
UY28209A1 (es) 2004-09-30
TNSN05206A1 (en) 2007-06-11
BRPI0407758A (pt) 2006-02-14
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
US20080015238A1 (en) 2008-01-17
AR043432A1 (es) 2005-07-27
PT1599455E (pt) 2009-09-29
AU2004215672B2 (en) 2010-01-07
NO20054398L (no) 2005-11-02
ECSP055985A (es) 2006-01-16
CA2516620A1 (fr) 2004-09-10
DE502004009690D1 (de) 2009-08-13
AU2004215677B2 (en) 2010-01-07
TW200500349A (en) 2005-01-01
RS20050594A (sr) 2007-12-31
HRP20050744A2 (en) 2006-09-30
EP1599455A1 (fr) 2005-11-30
TW200508210A (en) 2005-03-01
ZA200505765B (en) 2006-05-31
NO20054396L (no) 2005-11-11
BRPI0407814A (pt) 2006-02-14
DK1599452T3 (da) 2007-10-01
PE20050293A1 (es) 2005-05-24
DE502004004139D1 (de) 2007-08-02
CN100398526C (zh) 2008-07-02
US20080167354A1 (en) 2008-07-10
RU2005129992A (ru) 2006-02-10
RU2005130002A (ru) 2006-01-27
NO20054398D0 (no) 2005-09-22
MA27742A1 (fr) 2006-02-01
CA2517381A1 (fr) 2004-09-10
EP1599452A1 (fr) 2005-11-30
ES2287700T3 (es) 2007-12-16
US20050215596A1 (en) 2005-09-29
NO20054408D0 (no) 2005-09-22
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
AR043433A1 (es) 2005-07-27
DK1599453T3 (da) 2009-08-24
DE502004009453D1 (de) 2009-06-18
KR20050105492A (ko) 2005-11-04
CN1753881A (zh) 2006-03-29
IL170314A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
MA27909A1 (fr) Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents
MA30421B1 (fr) Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA27737A1 (fr) Dérivés de l'acide 3-(2-phényloxazol-4-ylméthoxy)cyclohexylméthoxyacétique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
MA31894B1 (fr) Composes organiques
EA200500054A1 (ru) Новые соединения, применимые для лечения ожирения, сахарного диабета ii типа и расстройств центральной нервной системы
MA32108B1 (fr) Derives d'indazole
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA31276B1 (fr) Amides substitués, procédé de production et d'utilisation desdits amides.
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
TN2009000138A1 (fr) Biaryl-ether-urees
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA31573B1 (fr) Derives d'acides tetramiques et tetroniques a substitution spirophenyle oxaspirocyclique
NO20033617L (no) Fremgangsmate for behandling av diabetes mellitus
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA32120B1 (fr) Nouveaux composes chimiques
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
DE60009777D1 (de) Verbindungen zur Behandlung und Vorsorge bei Diabetes
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques